Abcam, ab80375, Recombinant human cGKI protein

Size: 10µg
Recombinant human cGKI protein is a Human Full Length protein, expressed in Baculovirus infected Sf9 cells, with >70%, suitable for SDS-PAGE, FuncS.
Key facts
Purity:>70% SDS-PAGE,
Expression system:Baculovirus infected Sf9 cells,
Tags:Tag free,
Applications:SDS-PAGE, FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:Specific Activity: 0.85 pmoles/min/μg. Enzyme reaction is conducted in a buffer containing 50 mM HEPES (pH7.5), 10 mM MgCl2, 1 mM EGTA, 200 μM ATP, 0.01% Brij-35, and 2 μM substrate (SER/THR 14) at room temperature for 1 hour.,
Accession:Q13976,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 8Constituents: 20% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.395% Tris HCl, 0.05% Sorbitan monolaurate, ethoxylated, 0.0462% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CGKI also known as cyclic GMP-dependent protein kinase I or PKG I mechanically functions as an important player in the signaling pathways that depend on cyclic GMP (cGMP). cGKI is a serine/threonine protein kinase with a molecular mass of approximately 76 kilodaltons. It gets expressed in various tissues including vascular smooth muscle cells brain and platelets. The protein shows highest expression levels in tissues involved in smooth muscle regulation and neurological functions.
Biological function summary
The involvement of cGKI extends beyond basic signaling impacting diverse physiological processes. cGKI plays an important role in smooth muscle relaxation platelet function and nerve signaling. By phosphorylating various downstream targets cGKI affects muscle tone and neurotransmitter release. In the smooth muscle cGKI does not act independently but as part of a larger complex that modulates the cellular response to nitric oxide and natriuretic peptides.
Pathways
CGKI participates as an active component in the nitric oxide-cGMP signaling pathway. This pathway is significant in controlling vascular tone and neurotransmission. cGKI interacts with the proteins soluble guanylate cyclase and myosin light-chain phosphatase which together modulate blood vessel relaxation and contraction. Additionally cGKI plays a role in the cyclic nucleotide signaling pathways maintaining cardiovascular and neuronal health.
CGKI shows a connection to cardiovascular diseases and hypertension. Alterations in cGKI expression or function can lead to improper regulation of vascular tone contributing to elevated blood pressure. In the context of cardiovascular disorders cGKI interacts with proteins like PDE5A which also modulate cGMP levels in tissues. Understanding cGKI’s role in these diseases helps inform potential therapeutic targets for pharmacological intervention.